|

I-DXd Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: DS-7300a, Ifinatamab deruxtecan, MK-2400

Pipeline

Phase 2: 1Phase 1/2: 2

Top Sponsors

  • Merck Sharp & Dohme LLC3

Indications

  • Cancer3
  • Lung Cancer2
  • Small Cell Lung Cancer Extensive Stage1
  • Lung Neoplasm1
  • Esophageal Squamous Cell Carcinoma1

Other1 trial

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Phase 1/2

Lexington, Kentucky1 trial

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

University of Kentucky Chandler Medical Center ( Site 0019)

Phase 2

Pittsburgh, Pennsylvania1 trial

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

UPMC Hillman Cancer Center ( Site 1904)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.